Vagal Nerve Stimulation to Treat Disorders of Consciousness
Launched by FONDAZIONE IRCCS SAN GERARDO DEI TINTORI · Jul 11, 2025
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a treatment called transcutaneous auricular vagal nerve stimulation (taVNS) can help people with disorders of consciousness, such as coma or a minimally conscious state, recover awareness more quickly. The treatment involves using a small device to gently stimulate a nerve in the ear, which researchers hope will improve patients’ ability to respond and regain consciousness. The study will compare patients receiving the real nerve stimulation to those receiving a fake (sham) treatment to see if the active treatment leads to better recovery.
Adults who have recently experienced brain injury leading to coma or similar conditions may be eligible, as long as they have healthy skin on their ears and do not have certain serious health problems, implants like pacemakers, or are pregnant. Participants will receive the stimulation twice a day for one hour during the early phase of treatment and then once daily during rehabilitation. This study is not yet recruiting patients but aims to find out if this non-invasive therapy can support faster and better recovery of consciousness after severe brain injury.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years old;
- • any acquired cerebral damage of any known etiology;
- • diagnosis of coma, UWS, or MCS with the corresponding basal CRS-R (Coma Recovery Scale-Revised) score performed during the screening period from 7 to 15 days since admission in ICU;
- • intact ear skin;
- • availability of the device.
- Exclusion Criteria:
- • Patients with severe hemodynamic, respiratory, infectious, or neurological instability requiring active treatment requiring mechanical ventilation or vasoactive drugs or pending acute neurosurgical interventions;
- • Need for deep sedation, including general anesthetics (e.g., propofol) or a combination of central-acting sedatives;
- • Documented pregnancy;
- • Active implant (e.g., pacemaker, cochlear implant);
- • History of previous serious neurological disability before the brain injury;
- • Seizures or status epilepticus as cause sustaining the disorder of consciousness;
- • Patients already enrolled in another ongoing interventional trial.
About Fondazione Irccs San Gerardo Dei Tintori
Fondazione IRCCS San Gerardo dei Tintori is a leading research institution in Italy dedicated to advancing healthcare through innovative clinical trials and translational research. Affiliated with the Italian National Health Service, the foundation focuses on a wide range of medical disciplines, emphasizing patient-centered approaches and multidisciplinary collaboration. With a commitment to improving clinical outcomes, the foundation actively engages in the development and implementation of cutting-edge therapies and medical technologies, striving to enhance the quality of life for patients while contributing to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Parma, , Italy
Padova, , Italy
Rozzano, , Italy
Milano, , Italy
Bergamo, , Italy
Roma, , Italy
Genova, , Italy
Brescia, Bs, Italy
Monza, Mb, Italy
Como, , Italy
Varese, , Italy
Patients applied
Trial Officials
Giuseppe Citerio, MD, Full Professor
Principal Investigator
University of Milano-Bicocca / Fondazione IRCCS San Gerardo dei Tintori
Alberto Addis, MD
Study Director
Fondazione IRCCS San Gerardo dei Tintori
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported